Simplicity Wealth LLC Cuts Position in Amgen Inc. $AMGN

Simplicity Wealth LLC decreased its stake in Amgen Inc. (NASDAQ:AMGN) by 33.0% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 3,443 shares of the medical research company’s stock after selling 1,695 shares during the period. Simplicity Wealth LLC’s holdings in Amgen were worth $972,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently added to or reduced their stakes in AMGN. Brighton Jones LLC increased its stake in Amgen by 23.5% in the 4th quarter. Brighton Jones LLC now owns 27,468 shares of the medical research company’s stock valued at $7,159,000 after purchasing an additional 5,226 shares in the last quarter. Sivia Capital Partners LLC grew its holdings in Amgen by 10.6% in the second quarter. Sivia Capital Partners LLC now owns 1,186 shares of the medical research company’s stock valued at $331,000 after purchasing an additional 114 shares during the last quarter. McAdam LLC increased its position in shares of Amgen by 61.2% in the second quarter. McAdam LLC now owns 1,394 shares of the medical research company’s stock valued at $389,000 after buying an additional 529 shares in the last quarter. Plancorp LLC raised its stake in shares of Amgen by 2.7% during the 2nd quarter. Plancorp LLC now owns 3,156 shares of the medical research company’s stock worth $881,000 after buying an additional 84 shares during the last quarter. Finally, Magnus Financial Group LLC raised its stake in shares of Amgen by 20.1% during the 2nd quarter. Magnus Financial Group LLC now owns 1,453 shares of the medical research company’s stock worth $406,000 after buying an additional 243 shares during the last quarter. 76.50% of the stock is currently owned by institutional investors and hedge funds.

Insider Buying and Selling

In other news, EVP Murdo Gordon sold 6,879 shares of the company’s stock in a transaction dated Wednesday, November 12th. The shares were sold at an average price of $336.83, for a total transaction of $2,317,053.57. Following the completion of the transaction, the executive vice president owned 41,923 shares of the company’s stock, valued at $14,120,924.09. This represents a 14.10% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, SVP Rachna Khosla sold 890 shares of the stock in a transaction dated Wednesday, November 12th. The stock was sold at an average price of $336.24, for a total transaction of $299,253.60. Following the transaction, the senior vice president owned 7,082 shares in the company, valued at approximately $2,381,251.68. The trade was a 11.16% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Over the last ninety days, insiders have sold 10,908 shares of company stock worth $3,674,966. 0.76% of the stock is owned by company insiders.

Amgen Stock Performance

Shares of AMGN opened at $344.75 on Friday. Amgen Inc. has a 1 year low of $261.43 and a 1 year high of $349.98. The company’s 50 day simple moving average is $332.07 and its 200 day simple moving average is $307.54. The company has a market capitalization of $185.64 billion, a price-to-earnings ratio of 26.64, a PEG ratio of 3.09 and a beta of 0.45. The company has a debt-to-equity ratio of 5.45, a quick ratio of 0.99 and a current ratio of 1.28.

Amgen (NASDAQ:AMGN) last issued its quarterly earnings results on Tuesday, November 4th. The medical research company reported $5.64 earnings per share for the quarter, beating the consensus estimate of $5.01 by $0.63. The company had revenue of $9.56 billion during the quarter, compared to the consensus estimate of $8.98 billion. Amgen had a return on equity of 162.59% and a net margin of 19.47%.Amgen’s revenue was up 12.4% on a year-over-year basis. During the same period in the previous year, the firm posted $5.58 EPS. Amgen has set its FY 2025 guidance at 20.600-21.400 EPS. On average, sell-side analysts predict that Amgen Inc. will post 20.62 EPS for the current year.

Amgen Increases Dividend

The firm also recently announced a quarterly dividend, which will be paid on Friday, March 6th. Investors of record on Friday, February 13th will be paid a $2.52 dividend. The ex-dividend date is Friday, February 13th. This is an increase from Amgen’s previous quarterly dividend of $2.38. This represents a $10.08 annualized dividend and a yield of 2.9%. Amgen’s payout ratio is currently 77.90%.

Trending Headlines about Amgen

Here are the key news stories impacting Amgen this week:

• Positive Sentiment: Amgen announced a dividend increase to $2.52, reinforcing its income profile and making the stock more attractive to dividend-focused investors. This supports longer-term investor demand. Amgen (NASDAQ:AMGN) Has Announced That It Will Be Increasing Its Dividend To $2.52
• Positive Sentiment: Amgen expanded its obesity/GLP‑1 strategy via a collaboration with Ro, signaling potential new mid-term revenue streams if programs progress. Pipeline progress tends to boost investor sentiment for growth prospects. Amgen (AMGN) expands obesity strategy with Ro collaboration on GLP-1 therapies
• Positive Sentiment: The stock recently hit a 52-week high, reflecting recent buyer interest and validation of recent corporate moves and sentiment around the pipeline. Amgen stock hits 52-week high at $346.41
• Neutral Sentiment: Zacks notes AMGN is a trending stock on its platform, outlining investor attention and search interest but providing no new catalyst; useful context on market interest but not a direct driver. Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock
• Neutral Sentiment: Analyst commentary and deep-dive pieces (e.g., Seeking Alpha on MariTide obesity/T2D potential) highlight upside from R&D, but these are longer‑horizon, research-driven views rather than immediate catalysts. Amgen: A Buy In 2026 On Exciting MariTide Obesity – T2D Potential
• Negative Sentiment: Sagebrush has sued Amgen over disputes tied to the 340B program, introducing legal, reimbursement and stakeholder-risk that could pressure margins or create uncertainty around commercial terms. Litigation and policy disputes can weigh on near-term sentiment. Sagebrush sues Amgen over 340B program row
• Negative Sentiment: Sanford C. Bernstein downgraded Amgen to a Hold / lowered its rating, which can trigger selling or reduced conviction among institutional investors and contribute to downward pressure. Bernstein downgrades Amgen (AMGN) to a Hold

Analyst Upgrades and Downgrades

A number of brokerages recently commented on AMGN. The Goldman Sachs Group increased their price objective on shares of Amgen from $400.00 to $403.00 and gave the company a “buy” rating in a research note on Thursday, January 8th. DZ Bank increased their price target on shares of Amgen from $335.00 to $364.00 in a research report on Monday, November 10th. Royal Bank Of Canada raised their price objective on shares of Amgen from $330.00 to $335.00 and gave the stock an “outperform” rating in a research note on Thursday, January 8th. Truist Financial upped their target price on Amgen from $318.00 to $319.00 and gave the company a “hold” rating in a research note on Thursday, January 8th. Finally, Scotiabank started coverage on Amgen in a report on Thursday, November 13th. They set a “sector outperform” rating and a $385.00 target price on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, ten have issued a Buy rating, ten have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, Amgen currently has a consensus rating of “Moderate Buy” and a consensus price target of $339.24.

About Amgen

Amgen Inc (NASDAQ: AMGN) is a global biotechnology company founded in 1980 and headquartered in Thousand Oaks, California. The company focuses on discovering, developing, manufacturing and delivering human therapeutics that address serious illnesses. Amgen’s work centers on biologic medicines derived from cellular and molecular biology, with an emphasis on translating advances in human genetics and protein science into therapies for patients.

Amgen’s commercial portfolio has historically included biologics used in oncology, supportive care, nephrology, bone health and cardiovascular disease.